Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose
There is a lack of reliable biomarkers that correlate with active juvenile idiopathic arthritis (JIA). The S100A8/A9 heterodimer (calprotectin) and S100A12 are proinflammatory molecules that have been shown to correlate with risk of relapse in JIA. Our objectives were to compare calprotectin and S100A12 levels in children with newly diagnosed oligoarticular JIA to those of healthy controls and to determine whether baseline levels of these proteins in oligoarticular JIA are associated with disease course.
Methods
This was a prospective, observational cohort study of newly diagnosed oligoarticular JIA patients at Seattle Children’s Hospital. Plasma calprotectin and S100A12 levels were measured using commercially-available enzyme-linked immunosorbent assay (ELISA) kits and compared to healthy pediatric controls using the Wilcoxon rank sum test.
Results
The oligoarticular JIA cohort (n=25) was 68% female, with a mean age of 5.6 years (range 2.1-14.4 years) and the historic pediatric control group (n=30) was 67% female, with a mean age of 9.1 years (range 1.3-13.4 years). The oligoarticular JIA cohort had significantly elevated calprotectin levels (median 1246 ng/ul, range 202-5694) compared to controls (median 730 ng/ul, range 124-1668), p value 0.005. For S100A12, the oligoarticular JIA cohort again had significantly elevated levels (median 48,800 pg/ml, range 0-350,400) compared to controls (median 13,400 pg/ml, range 0-178,700), p value=0.002.
Conclusion
Patients with oligoarticular JIA have significantly higher calprotectin and S100A12 levels at the time of diagnosis compared to healthy controls. A longitudinal analysis is underway to determine if these baseline S100 protein levels correlate with subsequent disease course. A reliable biomarker to aid in the prediction of disease course at diagnosis would potentially allow providers to identify children who would benefit from earlier aggressive therapy.
Disclosure:
A. R. Aminoff,
None;
C. A. Wallace,
Amgen,
2,
Pfizer Inc,
2,
Amgen,
5,
Novartis Pharmaceutical Corporation,
5;
S. Ringold,
None;
A. Stevens,
None;
J. M. Foster,
None.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/s100-proteins-in-oligoarticular-juvenile-idiopathic-arthritis/